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In Brief
Mathur et al. describe a non-canonical function of the antiviral drug ganciclovir in microglia. Ganciclovir induces a type I interferon response and reduces neuroinflammation in a mouse model of multiple sclerosis. The innate immune adaptor STING is required for this activity of ganciclovir.
INTRODUCTION
Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, fronto-temporal dementia, and amyotrophic lateral sclerosis are associated with activation of predominantly innate immune pathways, referred to as neuroinflammation. During this process, microglia and other brain cells and, in some cases, infiltrating cells from the systemic environment secrete inflammatory cytokines and chemokines with positive and negative effects on the brain (Glass et al., 2010) . Interferons are one such class of cytokines with neuroprotective and neurotoxic properties (Deczkowska et al., 2016) . For example, the type II interferon, IFNg, previously considered proinflammatory, has recently been shown to contribute to immune surveillance in healthy brains (Kunis et al., 2013) . Similarly, the type I interferon IFNb was shown to negatively affect brain function during aging (Baruch et al., 2014) , and on the other hand, IFNb can serve a protective function and is used to dampen inflammation in active, relapsing multiple sclerosis (Group, 1993) . Additionally, the lack of IFNb signaling in neurons resulted in Lewy body and Parkinson's disease-like dementia in mice (Ejlerskov et al., 2015) . Together, these studies suggest that the relative levels of type I and type II interferons and the context in which they act have a profound effect on neuroinflammation and neurodegeneration (Deczkowska et al., 2016) .
The production of type I interferons can be induced by a number of pattern recognition receptors (Takeuchi and Akira, 2010) , which trigger signaling cascades and targeted immune responses. The presence of double-stranded (ds) viral DNA in the host cytoplasm, for example, is recognized by the recently discovered cyclic GMP-AMP synthetase (cGAS), which catalyzes production of the second messenger 2 0 3 0 -cyclic-GMP-AMP (cGAMP), a potent ligand of the signaling adaptor known as stimulator of interferon genes (STING/ MPYS/MITA/ERIS, encoded by TMEM173). This cascade further elicits activation of IKK and TBK1 kinases, NF-kB, and IRF3 transcription factors and production of IFNb (Ishikawa and Barber, 2008; Okabe et al., 2009; Schoggins et al., 2011; Sun et al., 2009) . STING has thus emerged as an attractive target for drug discovery, especially for cancer treatment (Ahn et al., 2015; Fu et al., 2015) , but little is known about the role of STING in the brain and whether it has a role in neuroinflammation and neurodegeneration.
Here, we show that the antiviral drug ganciclovir (GCV) induces a type I interferon response in microglia that depends on a functional STING pathway. In vivo, STING is expressed in microglia in the CNS and is upregulated in experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis. Treatment with GCV reduces STING expression, the microglial inflammatory signature, immune cell infiltration, and paralysis in the EAE mouse model in a STING-dependent fashion. Figure 1A ) and other nucleoside analogs of 2 0 -deoxyguanosine are effective anti-viral drugs for the treatment of Fold change is based on control treatment for the experiment. All GCV treatments were performed with 200 mM unless otherwise noted. Statistical tests: one-way ANOVA followed by Dunnett's multiple comparison test (G-I) and unpaired Student's t test (D-F). Error bars represent mean + SEM from 3 (cell lines) or 2 (primary cells) independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
RESULTS

GCV (
cytomegalovirus and herpesvirus infections (Faulds and Heel, 1990) . We recently reported that GCV, at therapeutic doses equivalent to those in humans, ameliorates the disease course and pathology of EAE in mice (Ding et al., 2014) . GCV exerted these effects, in part, by reducing immune cell infiltration and inhibiting the proliferation of microglia, the immune cells of the CNS. To understand the molecular basis of GCV activity, microglia-like BV-2 cells were stimulated with GCV, and 38 secreted proteins were measured using a Luminex-based array (Figures S1A and S1B). GCV treatment led to the upregulation of several antiviral proteins, and CXCL10 was most significantly overproduced ( Figure S1B ). Gene expression analysis of GCVtreated BV-2 cells (Figures S1C and S1D) using a microfluidic qRT-PCR panel that we created (consisting of 86 microglia genes; Table S1 ) showed upregulation of CXCL10 and type I interferons (Figures S1C and S1D). To corroborate these findings, primary microglia isolated from adult mice were treated with GCV and analyzed using the microfluidic panel.
As with BV-2 cells, primary microglia showed prominent induction of type I interferon-dependent gene expression after GCV treatment ( Figures 1B and 1C) , including CXCL10 and IFNb ( Figure 1D ). In addition, these genes were increased at the protein level as well ( Figure 1F ). Importantly, GCV not only activated this interferon response in mouse microglia but also in human induced pluripotent stem cell (iPSC)-derived microglia (iMGLs) ; Figure 1E ). We chose to use CXCL10 and IFNb as outcomes for GCV activity because these proteins were upregulated at transcript as well as protein levels across multiple microglial and myeloid cell types. GCV exhibited time-and dose-dependent activity without detectable toxicity ( Figures 1G-1I ). Hence, we conclude that these immune-modulatory effects of GCV are unlikely to be due to growth inhibition or cell death. In its canonical mechanism of action, GCV is phosphorylated by viral thymidine kinases (e.g., herpes simplex virus type 1 thymidine kinase, HSVtk) (Littler et al., 1992) and incorporated into cellular DNA, inhibiting replication (Matthews and Boehme, 1988) . In contrast, the GCV activity we describe did not require HSVtk or endogenous tk. The cells used in this study did not express viral tk (Figures S1E and S1F). Additionally, microglia isolated from adult tk1 knockout mice treated with GCV also produced CXCL10 and IFNb (Figures S1G and S1H), suggesting that thymidine kinase is dispensable for this activity of GCV.
In a cell-based model of inflammation where primary microglia or BV-2 cells were stimulated with IFNg and lipopolysaccharide (LPS), GCV led to significant transcriptional inhibition of several proinflammatory genes ( Figure S2A ). One of the most significantly reduced transcript and protein was NOS2/ iNOS , which further led to a reduction in neurotoxic microglial nitric oxide production ( Figures S2B and S2F) .
We tested if other compounds and antiviral drugs could induce a type I interferon response like GCV. The structurally related FDA-approved GCV analogs acyclovir (ACV) and penciclovir (PCV), or the endogenous molecules guanine and guanosine and structurally unrelated anti-viral drugs (structures shown in Figure S3 ) failed to induce CXCL10 mRNA (Figures 2B and 2C) , suggesting that the 1,3-dihydroxy-2-propoxymethyl group at N9 of the guanine ring is necessary for activity. In support of this notion, methylating the 1,3-dihydroxyl groups in GCV (MethylGCV) abrogated CXCL10-inducing activity, whereas providing 4 hydroxyl groups in GCV dimers synthesized using a reducible disulfide linker (thiol-GCV) or non-reducible polyethylene glycol (PEG) linkers (diGCV) at C6 of the guanine ring (structures shown in Figure 2A ) increased potency to induce CXCL10 ( Figures 2D and 2E ). Like GCV, diGCV as well as the PEGylated GCV monomer (monoGCV) dose-dependently induced CXCL10 without causing considerable toxicity ( Figures  2F-2I ). Additionally, monoGCV and diGCV potently reduced iNOS transcript and protein ( Figures S2C, S2D , and S2G) and nitric oxide production in IFNg/LPS-stimulated BV-2 cells ( Figure S2H ), and they induced CXCL10 independent of endogenous tk1 ( Figure S2I ).
Interferons activate the Jak/Stat signaling pathway to induce CXCL10 (Liu et al., 2011) , and we observed that GCV and diGCV similarly depend on this pathway (Figure 3) . Specifically, the Stat1 inhibitor fludarabine (Frank et al., 1999) or the Jak kinase inhibitors ruxolitinib and TG101348 (Zhou et al., 2014 ) strongly inhibited CXCL10 production in response to GCV and diGCV ( Figures 3A and 3F ) without causing toxicity (Figures 3B and 3G) . Likewise, small interfering RNA (siRNA) knockdown of Stat1 and Jak1, but not TLR3, reduced GCV activity ( Figures  3C, 3H , and 3I). Primary microglia from Stat1 knockout (KO) mice also significantly reduced CXCL10 or IFNb mRNA induction by GCV, monoGCV, and diGCV ( Figure 3D ). Additionally, the ability of GCV to suppress the inflammatory marker iNOS was dependent on Stat1 ( Figure 3E ). GCV and its derivatives might activate the Jak/Stat pathway either directly or through the production and autocrine signaling of IFNb through subsequent feedback loops, activating other pattern recognition receptors ( Figure 4A ). Indeed, neutralization of IFNb with an antibody partly reduced CXCL10 induction mRNA by GCV, monoGCV, or diGCV in BV-2 cells ( Figure 3J ).
Recent studies have shown that, upon sensing exogenous dsDNA in the cytoplasm, the enzyme cGAS catalyzes the formation of cGAMP (structure in Figure S3 ), which subsequently induces a potent interferon response (Hornung et al., 2014; Ishikawa et al., 2009) . Cyclic dinucleoside monophosphates (e.g., c-di-GMP; structure in Figure S3 ) can induce a similar response (Chin et al., 2013) . These dinucleotides activate the endoplasmic reticulum (ER) membrane adaptor protein STING, which then activates TANK binding kinase 1 (Tbk1), NF-kB, and IRF3 (Barber, 2015; Ishikawa and Barber, 2008 ) and downstream effector genes, including IFNb and CXCL10 ( Figure 4A ). Accordingly, and in line with previous studies (Gao et al., 2013) , cGAMP and c-diGMP strongly induced CXCL10 and IFNb in microglia ( Figure 4B ), as did the reported STING agonists 5,6-Dimethylxantheonone-4-acetic acid (DMXAA) and 10-carboxymethyl-9-acridanone (CMA) (Cavlar et al., 2013; Gao et al., 2013; Prantner et al., 2012;  Figure 4C ). GCV and diGCV also induced CXCL10 in the human monocyte cell line THP-1, whereas DMXAA, which is specific for mouse STING (Conlon et al., 2013) , did not ( Figure 4D ). Due to its apparent structural similarity, we hypothesized that diGCV, and possibly GCV cellular metabolites, may mimic cyclic dinucleotides and activate the STING pathway.
Excitingly, siRNA-mediated knockdown of STING in BV-2 cells largely abrogated the capacity of diGCV and, to a lesser extent, monomeric GCV to induce CXCL10 ( Figure 4E ). Moreover, primary microglia from STING gt/gt mice, which lack functional STING protein (Sauer et al., 2011) and do not respond to cGAMP, failed to induce CXCL10 and IFNb mRNA in response to GCV, monoGCV, and diGCV ( Figure 4F ). Consistent with GCV targeting the STING pathway, pharmacological inhibition of Tbk1 activity using the antagonist amlexanox and siRNAmediated knockdown of IRF3 inhibited the capacity of monomeric and dimeric GCV to induce CXCL10 mRNA (Figures 4G and 4H) . Furthermore, siRNA-mediated knockdown of the upstream activator cGAS did not affect the activity of GCV and diGCV to induce CXCL10 ( Figure 4I ). These data in aggregate show that, like the reported STING agonists (Burdette et al., 2011; Cavlar et al., 2013; Gao et al., 2013) , the ability of GCV and its derivatives to induce a type I interferon response in microglia-like cells requires a functional STING pathway and downstream Jak/Stat signaling. Native GCV and diGCV molecules did not bind strongly to purified mouse STING protein ( Figure 4J ). The possibilities that these molecules are prodrugs, which are modified intracellularly to be active, or that they bind to another target in the STING pathway remain to be elucidated.
To determine the involvement of STING in regulating microglial reactivity and neuroinflammation in vivo, we induced the autoimmune disease EAE in wild-type (WT) and STING gt/gt mice and treated them with GCV ( Figure 5A ). We found that STING was specifically expressed in microglia and not detectable in other CNS cell types ( Figure 5B ; Figure S4 ). Interestingly, EAE induction led to a dramatic increase in STING expression in Iba1 + myeloid cells as well as in Tmem119 + microglia, and GCV reversed this phenotype almost completely ( Figure 5B ). We next asked if STING was required for the therapeutic effects of GCV in the EAE mouse model. As we reported previously (Ding et al., 2014) , GCV drastically reduced disease severity in WT mice in three independent experiments ( Figure 5C ), lowering disease incidence by 60%-70% ( Figure 5D ) and lethality from 20% to 0% (Figure 5E ). Although mice lacking STING showed a very similar disease course as WT mice ( Figures 5C-5E ), GCV failed to significantly reduce disease severity ( Figure 5C ), incidence ( Figure 5D ), and lethality ( Figure 5E mice. It was shown that STING gt/gt mice exhibit attenuated EAE development compared with WT mice (Lemos et al., 2014 Figure 5F ), proliferating T cells ( Figure 5K ; Figure S6E ), and activated microglia ( Figure 6C) . Consistent with our published data (Ding et al., 2014) , GCV significantly decreased the numbers of bromodeoxyuridine (BrdU) + and PCNA + proliferating cells ( Figure 5F and S5), Figure 5J ; Figure S5 ) but did not change CD3 + BrdU + proliferating T cells ( Figure 5K ) in cerebella and spinal cords ( Figure S6 ) of WT mice with EAE. GCV treatment did not increase the number of cleaved caspase-3 + cells ( Figure S7 ), suggesting that the inhibition of myeloid proliferation by GCV was not due to induction of apoptosis. Additionally, GCV-treated WT EAE mice showed reduced expression of the microglia-specific marker Tmem119 ( Figure 5H ; Figures S4B and S8 ) and the microglial activation marker CD68 ( Figure 5I ; Figure S8 ). In stark contrast, and in agreement with the pre-clinical data above, GCV-treated STING gt/gt mice with EAE showed no reduction in overall cell proliferation ( Figure 5F ; Figures S5 and S6 ), Tmem119 expression ( Figure 5H ), myeloid cell activation ( Figure 5I ), proliferating myeloid cells ( Figure 5J ; Figures S5  and S6 ), or T cells ( Figure 5K ; Figure S6 ).
To deduce whether this effect of GCV on EAE was due to inhibition of infiltrating myeloid cells or resident CNS microglia, we isolated CD11b + myeloid cells from the cerebella of WT and STING gt/gt mice, with or without EAE, and analyzed CD45 immunoreactivity ( Figure 6 ). GCV treatment reduced total CD45 hi (Figure 6A) and CD11b + CD45 hi ( Figure 6B ) activated myeloid cells as well as Tmem119 + CD45 hi activated microglia ( Figure 6C ) in WT EAE but not in STING gt/gt mice, suggesting that GCV exerts its effects on both the infiltrating (Tmem119 -, CD45 hi ) as well as resident microglia in the CNS (Tmem119 + ). Interestingly, STING gt/gt mice with EAE had twice as many proliferating cells as WT mice (Figure 5F ), and showed a trend toward increasing overall T cell proliferation ( Figure 5K ), and CD68 and CD45 hi immunoreactivity ( Figures 5I and 6C) , suggesting an altered EAE pathology in these mice.
Finally, to elaborate these anti-inflammatory effects of GCV, we isolated CD11b + Tmem119 + microglia ( Figure 7A Error bars represent mean + SEM. Statistical tests: two-way ANOVA followed by Sidak's multiple comparisons test between the indicated groups. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Figures 7B  and 7C ). The most significant differences were found between WT PBS-and GCV-treated microglia (Table S2) , and they were all STING-dependent ( Figure 7D ), supporting our finding that GCV requires STING to regulate microglial activity. The most significantly modulated genes by GCV in microglia from WT mice with EAE ( Figure 7E ) are known to be associated with inflammation (Alox5, Faim3, Ctsb, Lyz1, Clec2i, and Apoe), small-molecule transport (Sidt1, Fabp5, and Slc25a31), and G-protein-coupled receptors (F2rl2). Inflammatory response was the most significant GO term associated with GCV versus PBS WT microglia from mice with EAE ( Figure 7F ). Interestingly, some genes (e.g., Ctsb, Apoe, and Lyz1) that were significantly downregulated with GCV treatment were recently described as diseaseassociated microglia (DAM) genes in microglia from Alzheimer's and Amyotrophic Lateral Sclerosis (ALS) mouse models (Keren-Shaul et al., 2017 with an independent RNA-seq study from microglia in diseased EAE mice (Lewis et al., 2014) and found that the majority of DAM genes were also upregulated in microglia from EAE mice. Further analysis of the most differentially expressed DAM genes in our study showed that GCV downregulated these genes in WT but not in STING gt/gt microglia from mice with EAE ( Figures  8A-8C ). Additionally, there was an overall increase in expression of homeostatic microglia genes with GCV treatment ( Figure 8D ). Type I interferon transcripts were undetectable in the RNA-seq dataset. However, a microfluidic array on mRNA from cerebella of EAE mice showed an increase in type I interferons and confirmed the downregulation of inflammatory microglial transcripts observed by RNA-seq in WT mice treated with GCV ( Figure S9 ). Thus, we conclude that GCV induces low therapeutic levels of IFNs and results in downregulation of disease-associated genes in a STING-dependent way, reducing inflammation.
GCV-treated WT microglia from the other groups (
DISCUSSION
In aggregate, these studies show that GCV reduces EAE in a STING-dependent fashion similar to DNA nanoparticles, which were recently shown to attenuate EAE (Lemos et al., 2014) . STING is highly regulated in microglia in vivo, and activation of the STING pathway reduces microglial reactivity and the neuroinflammatory disease EAE. Because excessive IFN production is linked to interferonopathies such as STING-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutiè res syndrome (Rodero and Crow, 2016) , it will be important to find the optimal therapeutic levels to activate the STING pathway in a beneficial way.
Ganciclovir is a widely used antiviral drug and a close analog of acyclovir, the first successful antiviral drug, described in 1977 to exploit viral thymidine kinase activity and inhibit viral replication (Elion et al., 1977) . After decades of highly effective use in humans, our study uncovered a remarkable non-canonical activity of GCV, but not acyclovir, that involves the innate immune receptor STING and a stereotypical cellular antiviral program. We show that GCV can exhibit dual function in microglia ( Figure S10 ): in the naive state, GCV induces microglia to be ''primed''; on the other hand, GCV reduces inflammation in active microglia. We propose that GCV pushes microglia toward a primed state. This multi-modality of GCV is unique and may, in part, be responsible for the continued strong success of GCV (and its pro-drug valganciclovir), in spite of many newer antiviral drugs. Lower doses of GCV elicited little to no effect in CNS demyelination and viral disease models in mice (Skripuletz et al., 2015) , suggesting that appropriate dosing is necessary for the novel properties observed here. Alternatively, it is also possible that Error bars represent mean + SEM. Statistical tests: differential expression analysis based on the negative binomial distribution using DEseq2. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. GCV does not cross the blood-brain barrier or is functional specifically in the EAE mouse model. Because of its growing relevance not only in anti-viral immune responses but possibly in sensing mitochondrial damage as well (West et al., 2015) , STING has become an attractive target for drug development itself (He et al., 2015) . In addition, mutations in STING are associated with vascular and pulmonary syndrome (Liu et al., 2014) and other autoimmune diseases (Jeremiah et al., 2014; Sharma et al., 2015) , STING-IRF3 stress is associated with alcoholic liver disease (Petrasek et al., 2013) , and haploinsufficiency in the STING activating kinase Tbk1 is associated with ALS and frontotemporal dementia (FTD) (Freischmidt et al., 2015; Pottier et al., 2015) . Our findings that GCV, and GCV dimers in particular, activate a type I interferon response in a STING-dependent way and reduce microglial proliferation and neuroinflammation in vivo open the possibility to develop a new class of drugs to treat neurodegenerative and related diseases where neuroinflammation has been implicated.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: He, S., Mao, X., Sun, H., Shirakawa, T., Zhang, H., and Wang, X. (2015 Fluor 488, 555, 594, 647 (1:500, Life technologies). Z stacks of images were taken on confocal microscope (Zeiss LSM700/880). Double positive cells were counted and images were analyzed using ImageJ.
Flow cytometry
All procedures were carried out at 4 C. For Figure 6 , upon reaching disease score of 2 or more, mice were perfused, cerebella from hemi brains of mice were chopped and homogenized using a Dounce homogenizer in 2ml cold Medium A (HBSS+ 15mM HEPES+0.05% glucose+ 1:500 DnaseI), filtered through 100mm cell strainer, rinsed with 5ml Medium A and centrifuged at 340 g for 5 mins. For myelin removal, the precipitate was resuspended in 25% standard isotonic percoll (25% Percoll in PBS, diluted with Medium A) and centrifuged at 950 g for 20 mins. Precipitated cells were washed with FACS buffer (PBS+1% BSA+2mM EDTA) twice and stained with 1:100 CD11b-PE, 1:100 CD45-APC and 16mg/ml rabbit anti-mouse Tmem119 antibodies (85-5 and 106-6, gifts from Ben Barres lab) for 30 mins at room temperature, followed by 1:500 donkey anti-Rabbit-Alexafluor488. Cells were washed and analyzed on BD AccuriC6 flow cytometer.
For RNA sequencing, EAE was induced as above and mice were sacrificed when control treated group reached EAE score of 2 or higher. Cerebella were homogenized using the method described above and CD11b + Tmem119
+ microglia ($20,000 per sample) were FACS sorted into 500ml RLT buffer (QIAGEN) and stored on À80 C.
STING binding assay
For the nitrocellulose membrane-binding assay, 35 S-labeled 2 0 3 0 -cGA s MP was used as a probe . Negatively charged 2 0 3 0 -cGAMP and its analogs do not bind the membrane unless they are bound to proteins. 35 S-labeled 2 0 3 0 -cGA s MP (500 pM) was mixed with 100nM mSTING and bound to the membrane. Different small molecules were then titrated to compete with the probe. The autoradiography signals were analyzed using ImageJ.
RNA sequencing RNA was extracted from isolated microglia using RNeasy Plus Micro kit (QIAGEN) and the quality assessed by Agilent 2100 Bioanalyzer (Stanford PAN facility). About 1ng RNA was converted to cDNA and amplified for 12 cycles using SMART-seq v4 Ultra Low input RNA kit for sequencing (Takara Bio USA) according to manufacturer's instructions. Amplified cDNA was then purified by immobilization on AMPure XP beads. Purified cDNA was normalized and tagmented for 5 mins using Nextera XT DNA library prep kit (Illumina). Unique indexes were then added to each sample, which were then amplified for 12 cycles. cDNA was purified using AMPure XP beads and quality assessed by Advanced Analytical Fragment Analyzer (Stanford PAN facility). Samples were then normalized and pooled together and sequenced on Illumina Novaseq 6000 (Novogene) to obtain 150bp paired-end reads.
The quality of fastq files was assessed using FASTQC (v 0.11.4) (Andrews, 2010) . Reads were trimmed to 75bp using fastX toolkit (v 0.0.14) (http://hannonlab.cshl.edu/fastx_toolkit/) to remove poor quality segments toward the end of the reads. Trimmed reads were mapped to mouse mm9 reference genome using STAR (v 2.5.1b) (Dobin et al., 2013) . Raw read counts were generated with STAR using the GeneCounts function.
QUANTIFICATION AND STATISTICAL ANALYSIS
The following statistical tests (Prism 7) were used unless otherwise noted. Two groups were compared using unpaired Student's t test. One-way ANOVA followed by Dunnett's multiple comparison test was used for drug treatment experiments with more than one drug, and all treatments were compared to vehicle treated controls. Two-way ANOVA followed by Sidak's multiple comparisons was used for experiments with two genotypes and two treatment conditions. For all figures *p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001.
RNA-seq differential expression
Differential expression in RNA-Seq was analyzed using the R DESeq2 package (Love et al., 2014) . Read counts were used as input and normalized using built-in algorithms in DESeq2. Pairwise comparisons among the 4 groups were done on all genes and 16570 genes with calculable fold changes (FC) and false discovery rates (fdr) were used for further analysis. Only the genes differentially expressed in at least one comparison (q < 0.05, n = 59) were included in the Principal Component Analysis (PCA) and in the hierarchical clustering. Normed PCA and hierarchical clustering were performed on rlog-transformed data using the ade4 (Dray and Dufour, 2007) and gplots (Warnes et al., 2016 ) R packages, respectively. False discovery rate was estimated using Benjamini and Hochberg approach (Benjamini and Hochberg, 1995) .
Gene Ontology (GO) analysis Gene Ontology terms defined the gene product properties and covered three domains: cellular component; molecular function and biological process.
For RNA-seq GO analysis, genes were ranked based on the p value of the differential expression analysis between WT PBS and WT GCV. Enrichment for GOs terms within the top 100 genes was tested with the topGO R package using the 16570 genes kept in the analysis as the background (Alexa and Rahnenfuhrer, 2010).
For microfluidic RT-PCR in primary microglia, the GO analysis was performed to identify GO terms with over-representation of genes when the genes upregulated with GCV (log 2 fold change > 0.1) were compared to all the genes measured by the Fluidigm platform (83 genes). Table S2 summarizes differentially expressed genes with p-and q-values from RNA-seq dataset between WT PBS versus WT GCV, WT PBS versus STING gt/gt PBS, and STING gt/gt PBS versus STING gt/gt GCV. The accession number for the raw and normalized RNA sequence data reported in this paper is NCBI GEO: GSE106692.
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